Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Liteling is a synthetic biology company that leverages its proprietary Enzyme-Catalyzed Synthesis (ECS) platform to produce high-value biochemicals. Based in Suzhou, China, the company focuses on the green manufacturing of ingredients such as Nicotinamide Mononucleotide (NMN), functional peptides, and specialized amino acids. Liteling's technology replaces traditional chemical synthesis with enzymatic processes, offering higher purity and lower environmental impact for the pharmaceutical, nutraceutical, and cosmetic sectors. The company operates as both a product manufacturer and a CDMO partner for complex molecule synthesis. By integrating computational biology and enzyme engineering, Liteling aims to scale the production of rare and difficult-to-synthesize natural compounds. Its flagship product, NMN, is widely used in the longevity and metabolic health markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Liteling.